key: cord-0840845-hpmoj4lg
authors: Connors, Jean M.; Brooks, Maria M.; Sciurba, Frank C.; Fu, Zhuxuan; Ridker, Paul M.
title: Clinical predictors of COVID‐19 severity and bleeding in the ACTIV‐4B COVID‐19 outpatient thrombosis prevention trial
date: 2022-04-11
journal: Am J Hematol
DOI: 10.1002/ajh.26553
sha: 0d352fb8dd0881fa55d6cdeb7184b56a2e79c432
doc_id: 840845
cord_uid: hpmoj4lg

Clinical predictors of COVID‐19 severity and bleeding in ACTIV‐4B[Image: see text]

primary analysis population was limited to randomized participants who took at least one dose of medication, all suspected primary endpoints occurring after randomization were adjudicated; this analysis includes all adjudicated primary endpoint events occurring in the complete set of randomized participants. The principal safety endpoints were ISTH defined major bleeding and clinically relevant non-major bleeding (CRNMB). 2 Bleeding events not meeting these definitions were classified as minor. Only suspected major or CRNMB bleeding events were adjudicated, however, all bleeding events were reviewed by investigators.

The cumulative incidence of each endpoint was estimated using Kaplan-Meier methods; differences by assigned treatment were tested with log rank statistics. Logistic regression was used for the occurrence of the primary endpoint, and Cox regression for time to the bleeding endpoint. Candidate explanatory variables included assigned treatment, all collected demographic and clinical history variables (age, sex, race/ethnicity, body mass index, history of smoking, past history of hypertension, diabetes, or venous thromboembolism), key laboratory variables (D-dimer, CRP, and creatinine clearance) and the number of days between SARS-CoV-2 test and randomization.

Multivariable logistic and Cox regression models were created by including all variables individually associated with the outcome (p < 0.10) and applying backward stepwise regression to sequentially remove each factor with a p-value ≥0.10. The c-statistic and Harrell's concordance index quantified the discrimination of the final logistic and Cox regression models, respectively.

Among all 657 randomized participants, 26 suspected primary endpoints occurred during the 45-day period after randomization with 24 confirmed by adjudication (3.6%). The majority (21/24) occurred following randomization but before participants initiated assigned treatment, a median interval of 3 days [first quartile (Q1) -third quartile (Q3): 2-5 days]. 1 All 24 confirmed events were hospitalizations for cardiovascular or pulmonary indications, with 23 admitted for progressive COVID-19 pneumonia, and 1 admitted for suspected myocardial infarction which was adjudicated as negative. Among the 23 patients hospitalized with progressive COVID-19 pneumonia, one non-fatal deep venous thromboembolism, one fatal pulmonary embolism, and one fatality due to respiratory failure also occurred during the 45-day treatment period. One death from prolonged respiratory failure occurring in the 30-day safety followup is not included in this analysis. In this population, the use of steroids and monoclonal antibodies, as well as vaccination rates, were low given the lack of availability of these treatments for outpatients during the enrollment period from September 2020 through June 2021.

Unadjusted risks of endpoint events, odds ratios, and hazards ratios for baseline variables are shown in Table 1 . The cumulative incidence of the adjudicated primary endpoint in all randomized participants is shown in Figure 1A . All adjudicated primary COVID-related hospitalizations occurred within 10 days of randomization. As 21 of the 24 primary outcome events occurred prior to initiating treatment, the risk did not differ by assigned treatment (log rank p = 0.78 Recognition of the clinical predictors associated with these events is of clinical importance to identify those with COVID-19 likely to rapidly progress who might benefit from early aggressive intervention.

Observational data from electronic health records and health claims database analyses have identified older age, obesity, co-morbid cardiac or pulmonary disease, elevated CRP, male sex, and race/ethnicity, as risks for increased morbidity and mortality associated with COVID-19. 3 

In addition to receiving research support from NIH to conduct this 

The data that support the findings of this study are available from NIH. 

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19: The ACTIV-4B Randomized Clinical Trial

Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019 in the US

Coronavirus Disease 2019 Case Surveillance -United States

Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission

Prognostic value of C-reactive protein in patients with Coronavirus

Risk factors for hospitalization among persons with COVID-19-Colorado

Characteristics Associated with Hospitalization Among Patients with COVID-19 -Metropolitan

Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Providers

Prevalence and Outcomes of D-Dimer Elevation in Hospitalized Patients With COVID-19

Monoclonal Antibody COVID-19 Infusion j Guidance Portal (hhs.gov)